The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis
- PMID: 16225599
- DOI: 10.1111/j.1365-2133.2005.06800.x
The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis
Abstract
Background: Interleukin (IL)-20 and IL-19 are recently discovered members of the IL-10 family of cytokines. The skin of transgenic mice overexpressing IL-20 shows histological changes resembling some of those seen in psoriasis, i.e. thickened epidermis, hyperkeratosis and a compact stratum corneum. IL-19 and IL-20, as well as their receptor complexes, IL-20Ralpha/IL-20Rbeta and IL-22Ralpha/IL-20Rbeta, are expressed in human skin.
Objectives: To study the dynamics of IL-19 and IL-20 gene expression as well as the expression of their receptor subunits in psoriatic skin lesions.
Methods: Punch biopsies from patients with plaque-type psoriasis were collected before, during and after 28 days of treatment with either calcipotriol or ciclosporin (CsA). IL-20, IL-19, IL-20Ralpha, IL-20Rbeta and IL-22Ralpha mRNA expression were determined by quantitative reverse transcriptase-polymerase chain reaction.
Results: We found IL-19 and IL-20 mRNA expression in lesional psoriatic skin to be strongly upregulated compared with nonlesional psoriatic skin by a factor of 65 and 22, respectively. In contrast to previous reports, IL-20Ralpha and IL-20Rbeta mRNA levels showed a modest but statistically significant decrease in lesional psoriatic skin compared with nonlesional psoriatic skin. During treatment with calcipotriol or CsA, IL-19 and IL-20 mRNA levels decrease in accordance with the clinical improvement of psoriasis. Neither IL-19, IL-20, nor receptor subunit mRNA expression in lesional psoriatic skin reaches the levels of nonlesional skin during this short-term treatment. These findings are in line with the residual disease activity observed at the end of treatment.
Conclusions: The increased IL-19 and IL-20 mRNA expression levels in lesional psoriatic skin suggest that these two cytokines play a role in the pathogenesis of psoriasis. An imbalance in the receptor complexes for IL-19 and IL-20 might contribute to their suspected pathogenic effects.
Similar articles
-
Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin.Br J Dermatol. 2004 Sep;151(3):600-7. doi: 10.1111/j.1365-2133.2004.06088.x. Br J Dermatol. 2004. PMID: 15377346
-
Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol.J Invest Dermatol. 2003 Dec;121(6):1306-11. doi: 10.1111/j.1523-1747.2003.12626.x. J Invest Dermatol. 2003. PMID: 14675174
-
Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin.J Invest Dermatol. 2005 Jun;124(6):1284-92. doi: 10.1111/j.0022-202X.2005.23749.x. J Invest Dermatol. 2005. PMID: 15955105
-
[Interleukin-20--a new target in psoriasis treatment].Ugeskr Laeger. 2008 Sep 1;170(36):2777-81. Ugeskr Laeger. 2008. PMID: 18761871 Review. Danish.
-
IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases.Expert Opin Ther Targets. 2011 Feb;15(2):119-26. doi: 10.1517/14728222.2011.534461. Epub 2010 Nov 12. Expert Opin Ther Targets. 2011. PMID: 21073280 Review.
Cited by
-
Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment.Arthritis Res Ther. 2012 Sep 24;14(5):R200. doi: 10.1186/ar4038. Arthritis Res Ther. 2012. PMID: 23006144 Free PMC article. Clinical Trial.
-
Serum Interleukin-19 Levels in Acne Vulgaris Patients of Varying Clinical Severity in Erbil City.Cureus. 2023 Nov 17;15(11):e48939. doi: 10.7759/cureus.48939. eCollection 2023 Nov. Cureus. 2023. PMID: 38106772 Free PMC article.
-
IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not.J Mol Med (Berl). 2009 May;87(5):523-36. doi: 10.1007/s00109-009-0457-0. Epub 2009 Mar 30. J Mol Med (Berl). 2009. PMID: 19330474
-
Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-α.PLoS One. 2016 Dec 22;11(12):e0167437. doi: 10.1371/journal.pone.0167437. eCollection 2016. PLoS One. 2016. PMID: 28005985 Free PMC article.
-
Targeting IL-10 Family Cytokines for the Treatment of Human Diseases.Cold Spring Harb Perspect Biol. 2019 Feb 1;11(2):a028548. doi: 10.1101/cshperspect.a028548. Cold Spring Harb Perspect Biol. 2019. PMID: 29038121 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical